<p>在从商业制药业务转向临床前生物技术的过程中，Aadi Bioscience 进行了品牌重塑，以更好地匹配其战略重启。</p>
<p>该公司周二宣布，从今往后将更名为 Whitehawk Therapeutics。其股票代码也将相应更新：从周三开始，它将在纳斯达克以 “WHWK” 交易，取代自 2021 年与 Aerpio Pharmaceuticals 合并以来一直使用的 “AADI” 符号。</p>
<p>新名称旨在更好地反映该生物技术公司 “演变和加速其抗体药物偶联物（ADCs）组合的速度、灵活性和精准度”，根据公告所述。</p>
<p>该组合由 Whitehawk 最近从药明生物和中国生物技术公司杭州 DAC 获得的三种 ADCs 组成。公司在 12 月宣布了这一交易，详细说明了计划支付 4400 万美元的预付款以获得这些资产，并提供高达 2.65 亿美元的开发里程碑付款和 5.4 亿美元的商业里程碑付款的额外承诺。</p>
<p>这三种 ADCs 现在被称为 HWK-007、HWK-016 和 HWK-206，正在开发作为潜在的治疗多种癌症的药物，包括肺癌、卵巢癌和神经内分泌肿瘤。</p>
<p>“通过利用成熟的肿瘤生物学基础并整合尖端技术，我们的战略旨在高效、有效地应对治疗最棘手癌症的挑战，” 首席执行官 Dave Lennon 博士在周二的公告中表示。</p>
<p>转向临床前开发是在该公司以前称为 Aadi 的几年后，该公司获得 FDA 批准其 Fyarro 用于治疗局部晚期不可切除或转移性恶性血管周围上皮样细胞肿瘤的成年人。</p>
<p>然而，最近，由于该药物的二期实体肿瘤试验——当时是 Aadi 管道中唯一的资产——在去年夏天面临失败，该公司暂停了该研究，并宣布裁员 80% 的研发团队。</p>
<p>到 12 月，Aadi 显然准备好进行一次全新的开始。在同一公告中详细说明 ADCs 许可交易时，该公司还分享了它已达成协议，将其 Fyarro 业务及相关基础设施，以及 Aadi 名称和商标，出售给日本的 Kaken Pharmaceutical。</p>
<p>该出售仍在待定中，但预计收益将资助 Whitehawk 的运营直到 2028 年底，该公司周二表示。</p>

AADI

WHWK

<p>Aadi Bioscience 已更名为 Whitehawk Therapeutics，转型为临床前生物技术公司。该公司将在纳斯达克以新股票代码 "WHWK" 进行交易。这一变化反映了其专注于抗体药物偶联物（ADCs）用于癌症治疗，已从药明生物和杭州 DAC 许可了三种 ADC。该公司计划通过将其 Fyarro 业务出售给 Kaken Pharmaceutical 来为运营提供资金，直至 2028 年。首席执行官 Dave Lennon 强调了利用创新技术应对棘手癌症的战略</p>

<p>Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its strategic reboot.</p>
<div class="lb-trans"><p>在从商业制药业务转向临床前生物技术的过程中，Aadi Bioscience 进行了品牌重塑，以更好地匹配其战略重启。</p>
</div><p>The company will henceforth be known as Whitehawk Therapeutics, it announced Tuesday. Its stock ticker will be updated accordingly: As of Wednesday, it will trade as “WHWK” on the Nasdaq, replacing the “AADI” symbol it’s held since going public in a 2021 merger with Aerpio Pharmaceuticals.</p>
<div class="lb-trans"><p>该公司周二宣布，从今往后将更名为 Whitehawk Therapeutics。其股票代码也将相应更新：从周三开始，它将在纳斯达克以 “WHWK” 交易，取代自 2021 年与 Aerpio Pharmaceuticals 合并以来一直使用的 “AADI” 符号。</p>
</div><p>The new name is aimed at better reflecting the biotech’s “evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision,” according to the announcement.</p>
<div class="lb-trans"><p>新名称旨在更好地反映该生物技术公司 “演变和加速其抗体药物偶联物（ADCs）组合的速度、灵活性和精准度”，根据公告所述。</p>
</div><p>That portfolio is comprised of a trio of ADCs that Whitehawk recently licensed from WuXi Biologics and Chinese biotech Hangzhou DAC. The company announced the deal in December, when it detailed a plan to pay $44 million upfront to license the assets, offering additional commitments of up to $265 million in development milestone payments and $540 million for commercial milestones.</p>
<div class="lb-trans"><p>该组合由 Whitehawk 最近从药明生物和中国生物技术公司杭州 DAC 获得的三种 ADCs 组成。公司在 12 月宣布了这一交易，详细说明了计划支付 4400 万美元的预付款以获得这些资产，并提供高达 2.65 亿美元的开发里程碑付款和 5.4 亿美元的商业里程碑付款的额外承诺。</p>
</div><p>The three ADCs, now known as HWK-007, HWK-016 and HWK-206, are being developed as potential treatments for a range of cancers including lung and ovarian cancers and neuroendocrine tumors.</p>
<div class="lb-trans"><p>这三种 ADCs 现在被称为 HWK-007、HWK-016 和 HWK-206，正在开发作为潜在的治疗多种癌症的药物，包括肺癌、卵巢癌和神经内分泌肿瘤。</p>
</div><p>“By leveraging the foundation of well-established tumor biology and integrating cutting-edge technologies, our strategy is designed to address the challenges of treating the most difficult cancers efficiently and effectively,” CEO Dave Lennon, Ph.D., said in Tuesday’s announcement.</p>
<div class="lb-trans"><p>“通过利用成熟的肿瘤生物学基础并整合尖端技术，我们的战略旨在高效、有效地应对治疗最棘手癌症的挑战，” 首席执行官 Dave Lennon 博士在周二的公告中表示。</p>
</div><p>The shift to preclinical development comes several years after the company formerly known as Aadi earned FDA approval for its Fyarro to treat adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors.</p>
<div class="lb-trans"><p>转向临床前开发是在该公司以前称为 Aadi 的几年后，该公司获得 FDA 批准其 Fyarro 用于治疗局部晚期不可切除或转移性恶性血管周围上皮样细胞肿瘤的成年人。</p>
</div><p>More recently, however, with a phase 2 solid tumor trial of the drug—then the only asset in Aadi’s pipeline—heading for failure last summer, the company halted the study and announced layoffs of 80% of its R&amp;D workforce.</p>
<div class="lb-trans"><p>然而，最近，由于该药物的二期实体肿瘤试验——当时是 Aadi 管道中唯一的资产——在去年夏天面临失败，该公司暂停了该研究，并宣布裁员 80% 的研发团队。</p>
</div><p>By December, Aadi was apparently ready for a completely fresh start. In the same announcement detailing the ADC licensing deal, the company shared that it had also reached an agreement to sell off its Fyarro business and associated infrastructure, plus the Aadi name and trademark, to Japan’s Kaken Pharmaceutical.</p>
<div class="lb-trans"><p>到 12 月，Aadi 显然准备好进行一次全新的开始。在同一公告中详细说明 ADCs 许可交易时，该公司还分享了它已达成协议，将其 Fyarro 业务及相关基础设施，以及 Aadi 名称和商标，出售给日本的 Kaken Pharmaceutical。</p>
</div><p>That divestment is still pending, but the proceeds are expected to fund Whitehawk’s operations through the end of 2028, it said Tuesday.</p>
<div class="lb-trans"><p>该出售仍在待定中，但预计收益将资助 Whitehawk 的运营直到 2028 年底，该公司周二表示。</p>
</div>

Aadi 起飞，改名为 Whitehawk Therapeutics